wilate human coagulation factor viii 900 iu and von willebrand factor 800 iu powder for injection vial with diluent vial
octapharma australia pty ltd - von willebrand factor, quantity: 800 iu; factor viii, quantity: 900 iu; factor viii, quantity: 15 mg - injection, powder for - excipient ingredients: calcium chloride dihydrate; glycine; sodium chloride; sucrose; octoxinol 9; tributyl phosphate; sodium citrate dihydrate - 1. von willebrand disease (vwd): treatment of bleeding episodes including surgical bleeding in patients with von willebrand's disease when desmopressin treatment is ineffective or contraindicated. 2. haemophilia a: treatment and prophylaxis of bleeding including surgical bleeding in patients with haemophilia a (congenital fviii deficiency). there are insuffcient data to recommend the use of wilate in children less than 12 years of age.
dried factor viii fraction, type 8y
bio products laboratory limited dagger lane, elstree hertfordshire, wd6 3bx, united kingdom - factor viii, human - powder and solvent for solution for injection - factor viii, human 25 iu/ml - antihemorrhagics
csl chile human coagulation factor viii for injection 500iu
csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl chile human coagulation factor viii for injection 250iu
csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl ecuador human coagulation factor viii for injection 250iu
csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl panama human coagulation factor viii for injection 250iu
csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl colombia human coagulation factor viii for injection 250iu
csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl guatemala human coagulation factor viii for injection 500iu
csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl guatemala human coagulation factor viii for injection 250iu
csl behring australia pty ltd - factor viii, quantity: 250 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.
csl el salvador human coagulation factor viii for injection 500iu
csl behring australia pty ltd - factor viii, quantity: 500 iu - injection, solution - excipient ingredients: water for injections - human coagulation factor viii is indicated for the treatment and prophylaxis of bleeding associated with factor viii deficiency due to haemophilia a.